

API	Indication	R&D Validation batches	DMF
RESPIRATORY			
Abediterol	Asthma and COPD	early R&D	
Acidinium	COPD treatment	early R&D	
Arformoterol tartrate ^P	Asthma / COPD (Inhaled)	√	√
Batefenterol	COPD treatment	early R&D	
Formoterol	Asthma and COPD	√ ^{CoS}	√
Glycopyrrolate Br ^P	COPD with chronic bronchitis	√	2017
Indacaterol ^P	Asthma / COPD (Inhaled)	√	2019
Olodaterol	Asthma / COPD (Inhaled)	2017	
Revefenacin	COPD treatment	early R&D	
Salmeterol xinafoate ^P	Asthma and COPD	√ ^{CoS}	√
Tiotropium Bromide	Chronic obstructive pulmonary disease	2018	
Umeclidinium	COPD treatment	2017	
Vilanterol trifenate	COPD with chronic bronchitis	2018	
GENERIC			
Apixaban	Venous thromboembolism	√	2017
Aprepitant	Emesis	√	2017
Asenapine ^P	Schizophrenia and acute mania	√	√
Brivaracetam	Antiepileptic	early R&D	
Carvedilol	Hypertension, angina, heart failure	√	√
Cinacalcet	Hyperparathyroidism / Hypercalcaemia	√	2018
Clevidipine	Hypertension	early R&D	
Clomethiazole	Insomnia	early R&D	
Crisaborole	Atopic dermatitis and psoriasis	√	2019
Desloratadine	Allergy	√	√
Dronedarone	Atrial fibrillation & general arrhythmia	√	√
Eletriptan HBr	Migraine	√	2017
Enalapril maleate	Hypertension	√	√

CoS = Products with Certificate of Suitability

P = Patent applications/granted patents owned by Invent Farma Group

Products protected by valid patents are developed with no commercial purposes. These products are under development for uses related to the activities stated in the Hatch-Waxman Act [35 U.S.C. §271(e)(1)]. These products are solely for uses related to the development and submission of information to obtain a marketing authorization. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.

API	Indication	R&D Validation batches	DMF
GENERICs			
Fluconazol	Antifungal	√ ^{CoS}	√
Granisetron base	Emesis	√	√
Granisetron HCl	Emesis	√ ^{CoS}	√
lloperidone	Schizophrenia and other psychotic disorders	√	
Imidafenacin	Urinary incontinence	√	2018
Imidapril	Hypertension	√	√
Loratadine	Allergy	√	√
Luliconazole	Antifungal	√	2019
Montelukast sodium	Asthma, allergic & seasonal rhinitis	√	√
Nitrendipine	Hypertension	√ ^{CoS}	√
Olanzapine	Schizophrenia, psychosis	√	√
Olanzapine pamoate (sterile)	Schizophrenia, psychosis	√	2019
Olmesartan medoxomil	Hypertension	√	
Ondansetron base ^P	Emesis	√	√
Ondansetron hydrochloride	Emesis	√ ^{CoS}	√
Prasugrel base ^P	Prophylaxis and therapy of thrombosis	√	√
Prasugrel hydrochloride	Prophylaxis and therapy of thrombosis	√	
Quetiapine hemifumarate	Schizophrenia, psychosis	√	√
Risperidone (sterile)	Schizophrenia, psychosis	√ ^{CoS}	√
Rivaroxaban	Thrombosis. Stroke	√	2018
Rizatriptan benzoate	Migraine	√	√
Roflumilast	COPD with chronic bronchitis	2017	
Telmisartan	Hypertension	√	√
Tetrabenazine	Parkinson disease	√	
(+) Tetrabenazine	Parkinson disease	√	
Tolvaptan	Hiponatremia	√	2018
Zolmitriptan	Migraine	√	√

CoS = Products with Certificate of Suitability

P = Patent applications/granted patents owned by Invent Farma Group

Products protected by valid patents are developed with no commercial purposes. These products are under development for uses related to the activities stated in the Hatch-Waxman Act [35 U.S.C. §271(e)(1)]. These products are solely for uses related to the development and submission of information to obtain a marketing authorization. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.